Continuous Versus Intermittent Infusion of Beta-lactam Antibiotics: Where Do We Stand Today? A Narrative Review

Overview

Journal Germs

Specialty Infectious Diseases

Date 2024 Nov 4

PMID 39493742

Authors

Basil Alawyia

Sarah Fathima

Nikolaos Spernovasilis

Danny Alon-Ellenbogen

Affiliations

Soon will be listed here.

Abstract

Introduction: Antimicrobial resistance (AMR) is among the greatest threats to global healthcare. The World Health Organization (WHO) estimates that by 2050 ten million deaths will be attributed to AMR annually. In response, the WHO has implemented antibiotic stewardship programs which focus on optimizing antibiotic use and raise, amongst others, the issue of the preferred method of intravenous antibiotic administration. Various studies have attempted to answer this question with conflicting results.

Review: This review examined several studies assessing extended/continuous infusion compared to intermittent infusion of three beta-lactams: piperacillin-tazobactam, cefepime, and meropenem. The findings and conclusions of each study were summarized and compared to one another to provide a general overview of the current evidence.

Conclusions: We conclude that continuous/extended infusion showed a greater clinical benefit in highly critical cases, namely sepsis and febrile neutropenia, compared to intermittent infusion. Additionally, in cases where a pathogen was identified, continuous/extended infusion showed superiority. Nonetheless, high-quality studies with larger samples are needed to demonstrate the difference between these two modes of infusion in a way that would better inform guidelines and policies, aiding in the fight against AMR.

References

Cotner S, Cliff Rutter W, Burgess D, Wallace K, Martin C, Burgess D . Influence of β-Lactam Infusion Strategy on Acute Kidney Injury. Antimicrob Agents Chemother. 2017; 61(10). PMC: 5610533. DOI: 10.1128/AAC.00871-17. View

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

Ahmed N, Jen S, Altshuler D, Papadopoulos J, Pham V, Dubrovskaya Y . Evaluation of Meropenem Extended Versus Intermittent Infusion Dosing Protocol in Critically Ill Patients. J Intensive Care Med. 2018; 35(8):763-771. DOI: 10.1177/0885066618784264. View

Shoji K, Bradley J, Reed M, van den Anker J, Domonoske C, Capparelli E . Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrob Agents Chemother. 2016; 60(4):2150-6. PMC: 4808231. DOI: 10.1128/AAC.02592-15. View

Zhao H, Gu J, Lyu J, Liu D, Wang Y, Liu F . Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Chin Med J (Engl). 2017; 130(10):1139-1145. PMC: 5443018. DOI: 10.4103/0366-6999.205859. View

Cutro S, Holzman R, Dubrovskaya Y, Chen X, Ahuja T, Scipione M . Extended-Infusion versus standard-infusion piperacillin-tazobactam for sepsis syndromes at a tertiary medical center. Antimicrob Agents Chemother. 2014; 58(8):4470-5. PMC: 4136013. DOI: 10.1128/AAC.02759-14. View

Sprauten P, Beringer P, Louie S, Synold T, Gill M . Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother. 2003; 47(6):1991-4. PMC: 155835. DOI: 10.1128/AAC.47.6.1991-1994.2003. View

Leegwater E, Wewerinke L, de Grauw A, van Veen M, Storm B, Kruizinga M . Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration. Clin Pharmacokinet. 2023; 62(5):715-724. DOI: 10.1007/s40262-023-01230-w. View

Hong L, Downes K, FakhriRavari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S . International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of.... Pharmacotherapy. 2023; 43(8):740-777. DOI: 10.1002/phar.2842. View

10.

Tournayre S, Mathieu O, Villiet M, Besnard N, Brunot V, Daubin D . Factors associated with meropenem pharmacokinetic/pharmacodynamic target attainment in septic critically ill patients treated with extended intermittent infusion or continuous infusion. Int J Antimicrob Agents. 2023; 62(2):106868. DOI: 10.1016/j.ijantimicag.2023.106868. View

11.

Feher C, Rovira M, Soriano A, Esteve J, Martinez J, Marco F . Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014; 69(9):2556-62. DOI: 10.1093/jac/dku150. View

12.

Abdul-Aziz M, Sulaiman H, Mat-Nor M, Rai V, Wong K, Hasan M . Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016; 42(10):1535-1545. DOI: 10.1007/s00134-015-4188-0. View

13.

Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W . Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents. 2011; 38(3):231-6. DOI: 10.1016/j.ijantimicag.2011.04.019. View

14.

Zembles T, Schortemeyer R, Kuhn E, Bushee G, Thompson N, Mitchell M . Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients. J Pediatr Pharmacol Ther. 2021; 26(2):187-193. PMC: 7887888. DOI: 10.5863/1551-6776-26.2.187. View

15.

Chen M, Buurma V, Shah M, Fahim G . Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics. Am J Health Syst Pharm. 2019; 76(18):1383-1394. DOI: 10.1093/ajhp/zxz154. View

16.

Kebudi R, Kizilocak H . Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment. Curr Pediatr Rev. 2018; 14(3):204-209. DOI: 10.2174/1573396314666180508121625. View

17.

Cao G, Zhou P, Zhang H, Sun B, Tong X, Xing Y . Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study. Antibiotics (Basel). 2022; 11(3). PMC: 8944670. DOI: 10.3390/antibiotics11030341. View

18.

Hyun D, Seo J, Lee S, Ahn J, Hong S, Lim C . Continuous Piperacillin-Tazobactam Infusion Improves Clinical Outcomes in Critically Ill Patients with Sepsis: A Retrospective, Single-Centre Study. Antibiotics (Basel). 2022; 11(11). PMC: 9686508. DOI: 10.3390/antibiotics11111508. View

19.

Monti G, Bradic N, Marzaroli M, Konkayev A, Fominskiy E, Kotani Y . Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA. 2023; 330(2):141-151. PMC: 10276329. DOI: 10.1001/jama.2023.10598. View

20.

Debray A, Callot D, Hirt D, Bille E, Renolleau S, Chouchana L . Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study. Eur J Pediatr. 2022; 182(3):965-973. DOI: 10.1007/s00431-022-04716-0. View